▶ 調査レポート

全身性エリテマトーデス治療の世界市場:市場規模、シェア、成長、動向、予測

• 英文タイトル:Systemic Lupus Erythematosus Treatment Market (Drug: Antimalarial Drugs (Chloroquine and Hydrochloroquine), Non-steroidal Anti-inflammatory Drugs (NSAIDS) (Ibuprofen, Naproxen, and Others), Corticosteroids (Prednisone, Hydrocortisone, Dexamethasone, and Others), Immunosuppressive Drugs (Azathioprine, Cyclophosphamide, Methotrexate, and Others], Others (Biologics, B-cell Modulators, etc.); Mode of Delivery: Intravenous, Subcutaneous, and Oral; Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Sales) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

Transparency Market Researchが調査・発行した産業分析レポートです。全身性エリテマトーデス治療の世界市場:市場規模、シェア、成長、動向、予測 / Systemic Lupus Erythematosus Treatment Market (Drug: Antimalarial Drugs (Chloroquine and Hydrochloroquine), Non-steroidal Anti-inflammatory Drugs (NSAIDS) (Ibuprofen, Naproxen, and Others), Corticosteroids (Prednisone, Hydrocortisone, Dexamethasone, and Others), Immunosuppressive Drugs (Azathioprine, Cyclophosphamide, Methotrexate, and Others], Others (Biologics, B-cell Modulators, etc.); Mode of Delivery: Intravenous, Subcutaneous, and Oral; Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Sales) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027 / TPM-NV154資料のイメージです。• レポートコード:TPM-NV154
• 出版社/出版日:Transparency Market Research / 2019年10月28日
• レポート形態:英文、PDF、211ページ
• 納品方法:Eメール
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥620,065 (USD5,795)▷ お問い合わせ
  Multi User¥941,065 (USD8,795)▷ お問い合わせ
  Global Site License¥1,262,065 (USD11,795)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本資料は、全身性エリテマトーデス治療の世界市場について調べ、全身性エリテマトーデス治療の世界市場規模、市場動向、市場シェア、市場環境、市場予測、薬物別(抗マラリア薬(クロロキンおよびヒドロクロロキン)、非ステロイド系抗炎症薬(NSAIDS)(イブプロフェン、ナプロキセン、およびその他)、コルチコステロイド(プレドニゾン、ヒドロコルチゾン、デキサメタゾン、およびその他)、免疫抑制薬(アザチオプリン、シクロトレキサミド、シクロトホスファミド、 およびその他]、その他(生物製剤、B細胞モジュレーターなど))分析、デリバリー方法別(静脈内、皮下、および経口)分析、流通チャンネル別(病院薬局、小売薬局、およびオンライン販売)分析、関連企業情報などをまとめました。
・全身性エリテマトーデス治療の市場概要
・全身性エリテマトーデス治療の市場動向
・全身性エリテマトーデス治療の世界市場規模・予測
・全身性エリテマトーデス治療市場:薬物別(抗マラリア薬(クロロキンおよびヒドロクロロキン)、非ステロイド系抗炎症薬(NSAIDS)(イブプロフェン、ナプロキセン、およびその他)、コルチコステロイド(プレドニゾン、ヒドロコルチゾン、デキサメタゾン、およびその他)、免疫抑制薬(アザチオプリン、シクロトレキサミド、シクロトホスファミド、 およびその他]、その他(生物製剤、B細胞モジュレーターなど))
・全身性エリテマトーデス治療市場:デリバリー方法別(静脈内、皮下、および経口)
・全身性エリテマトーデス治療市場:デリバリー方法別(静脈内、皮下、および経口)
・地域別分析(北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米)
・競争環境・関連企業分析

Although healthcare companies in the systemic lupus erythematosus treatment market have made significant advances regarding drug development, certain side effects of these drugs are anticipated to negatively influence market growth. For instance, immunosuppressive drugs are estimated to reach a value of ~US$ 1.5 billion by 2027, and continue to dominate the systemic lupus erythematosus treatment market throughout the forecast period. However, enduring disease activity with recurring flare ups and accumulating toxicity due to glucocorticoids (GC) and immunosuppressive (IS) medications are some of the side effects associated with SLE drugs.

Since SLE is a heterogeneous disease of varying severity, healthcare companies in the systemic lupus erythematosus treatment landscape are beginning to understand that, developing ‘one size fits all’ immunosuppressive drugs increases the burden of symptoms in patients. This is why, healthcare companies in the systemic lupus erythematosus treatment market are adopting the ‘treat-to-target’ approach to develop drugs that effectively manage and minimize the incidence of disease activity. Healthcare providers are implementing patient-tailored therapeutic strategies with the introduction of improved biologic agents.

レポート目次

1. Preface

1.1. Report Scope and Market Segmentation

1.2. Research Highlights

2. Assumptions and Research Methodology

2.1. Assumptions

2.2. Research Methodology

3. Executive Summary

3.1. Global Systemic Lupus Erythematosus Treatment Market Snapshot

4. Market Overview

4.1. Product Overview

4.2. Key Industry Events

4.3. Market Dynamics

4.3.1. Drivers and Restraints Snapshot Analysis

4.3.2. Drivers

4.3.3. Restraints

4.3.4. Opportunities

4.4. Global Systemic Lupus Erythematosus Treatment Market Revenue Projection

4.5. Global Systemic Lupus Erythematosus Treatment Market Outlook

5. Market Outlook

5.1. Key Mergers & Acquisitions

5.2. Pipeline Analysis

5.3. Disease Prevalence & Incidence Rate Globally with Key Countries

6. Global Systemic Lupus Erythematosus Treatment Market Analysis, by Drug

6.1. Introduction

6.2. Global Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Drug

6.3. Global Systemic Lupus Erythematosus Treatment Market Forecast, by Drug

6.3.1. Antimalarial Drugs

6.3.1.1. Chloroquine

6.3.1.2. Hydrochloroquine

6.3.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)

6.3.2.1. Ibuprofen

6.3.2.2. Naproxen

6.3.2.3. Others

6.3.3. Corticosteroids

6.3.3.1. Prednisone

6.3.3.2. Hydrocortisone

6.3.3.3. Dexamethasone

6.3.3.4. Others

6.3.4. Immunosuppressive Drugs

6.3.4.1. Azathioprine

6.3.4.2. Cyclophosphamide

6.3.4.3. Methotrexate

6.3.4.4. Others

6.3.5. Others (Biologics, B-cell Modulators, etc.)

7. Global Systemic Lupus Erythematosus Treatment Market Analysis, by Mode of Delivery

7.1. Introduction

7.2. Global Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Mode of Delivery

7.3. Global Systemic Lupus Erythematosus Treatment Market Forecast, by Mode of Delivery

7.3.1. Intravenous

7.3.2. Subcutaneous

7.3.3. Oral

7.4. Global Systemic Lupus Erythematosus Treatment Market Analysis, by Mode of Delivery

8. Global Systemic Lupus Erythematosus Treatment Market Analysis, by Distribution Channel

8.1. Introduction

8.2. Global Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel

8.3. Global Systemic Lupus Erythematosus Treatment Market Forecast, by Distribution Channel

8.3.1. Hospital Pharmacies

8.3.2. Retail Pharmacies

8.3.3. Online Sales

8.4. Global Systemic Lupus Erythematosus Treatment Market Analysis, by Distribution Channel

9. Global Systemic Lupus Erythematosus Treatment Market Analysis, by Region

9.1. Global Systemic Lupus Erythematosus Treatment Market Scenario, by Country

9.2. Global Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Region

9.3. Global Systemic Lupus Erythematosus Treatment Market Forecast, by Region

9.3.1. North America

9.3.2. Europe

9.3.3. Asia Pacific

9.3.4. Latin America

9.3.5. Middle East & Africa

10. North America Systemic Lupus Erythematosus Treatment Market Analysis

10.1. Key Findings

10.2. North America Systemic Lupus Erythematosus Treatment Market Overview

10.3. North America Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Country

10.4. North America Systemic Lupus Erythematosus Treatment Market Forecast, by Country

10.4.1. U.S.

10.4.2. Canada

10.5. North America Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Drug

10.6. North America Systemic Lupus Erythematosus Treatment Market Forecast, by Drug

10.6.1. Antimalarial Drugs

10.6.1.1. Chloroquine

10.6.1.2. Hydrochloroquine

10.6.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)

10.6.2.1. Ibuprofen

10.6.2.2. Naproxen

10.6.2.3. Others

10.6.3. Corticosteroids

10.6.3.1. Prednisone

10.6.3.2. Hydrocortisone

10.6.3.3. Dexamethasone

10.6.3.4. Others

10.6.4. Immunosuppressive Drugs

10.6.4.1. Azathioprine

10.6.4.2. Cyclophosphamide

10.6.4.3. Methotrexate

10.6.4.4. Others

10.6.5. Others (Biologics, B-cell Modulators, etc.)

10.7. North America Systemic Lupus Erythematosus Treatment Market Value Share Analysis, by Mode of Delivery

10.8. North America Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Mode of Delivery

10.8.1. Intravenous

10.8.2. Subcutaneous

10.8.3. Oral

10.9. North America Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel

10.10. North America Systemic Lupus Erythematosus Treatment Market Forecast, by Distribution Channel

10.10.1. Hospital Pharmacies

10.10.2. Retail Pharmacies

10.10.3. Online Sales

11. Europe Systemic Lupus Erythematosus Treatment Market Analysis

11.1. Key Findings

11.2. Europe Systemic Lupus Erythematosus Treatment Market Overview

11.3. Europe Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region

11.4. Europe Systemic Lupus Erythematosus Treatment Market Forecast, by Country/Sub-region

11.4.1. Germany

11.4.2. U.K.

11.4.3. France

11.4.4. Spain

11.4.5. Italy

11.4.6. Rest of Europe

11.5. Europe Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Drug

11.6. Europe Systemic Lupus Erythematosus Treatment Market Forecast, by Drug

11.6.1. Antimalarial Drugs

11.6.1.1. Chloroquine

11.6.1.2. Hydrochloroquine

11.6.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)

11.6.2.1. Ibuprofen

11.6.2.2. Naproxen

11.6.2.3. Others

11.6.3. Corticosteroids

11.6.3.1. Prednisone

11.6.3.2. Hydrocortisone

11.6.3.3. Dexamethasone

11.6.3.4. Others

11.6.4. Immunosuppressive Drugs

11.6.4.1. Azathioprine

11.6.4.2. Cyclophosphamide

11.6.4.3. Methotrexate

11.6.4.4. Others

11.6.5. Others (Biologics, B-cell Modulators, etc.)

11.7. Europe Systemic Lupus Erythematosus Treatment Market Value Share Analysis, by Mode of Delivery

11.8. Europe Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Mode of Delivery

11.8.1. Intravenous

11.8.2. Subcutaneous

11.8.3. Oral

11.9. Europe Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel

11.10. Europe Systemic Lupus Erythematosus Treatment Market Forecast, by Distribution Channel

11.10.1. Hospital Pharmacies

11.10.2. Retail Pharmacies

11.10.3. Online Sales

12. Asia Pacific Systemic Lupus Erythematosus Treatment Market Analysis

12.1. Key Findings

12.2. Asia Pacific Systemic Lupus Erythematosus Treatment Market Overview

12.3. Asia Pacific Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region

12.4. Asia Pacific Systemic Lupus Erythematosus Treatment Market Forecast, by Country/Sub-region

12.4.1. Japan

12.4.2. China

12.4.3. India

12.4.4. Australia & New Zealand

12.4.5. Rest of Asia Pacific

12.5. Asia Pacific Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Drug

12.6. Asia Pacific Systemic Lupus Erythematosus Treatment Market Forecast, by Drug

12.6.1. Antimalarial Drugs

12.6.1.1. Chloroquine

12.6.1.2. Hydrochloroquine

12.6.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)

12.6.2.1. Ibuprofen

12.6.2.2. Naproxen

12.6.2.3. Others

12.6.3. Corticosteroids

12.6.3.1. Prednisone

12.6.3.2. Hydrocortisone

12.6.3.3. Dexamethasone

12.6.3.4. Others

12.6.4. Immunosuppressive Drugs

12.6.4.1. Azathioprine

12.6.4.2. Cyclophosphamide

12.6.4.3. Methotrexate

12.6.4.4. Others

12.6.5. Others (Biologics, B-cell Modulators, etc.)

12.7. Asia Pacific Systemic Lupus Erythematosus Treatment Market Value Share Analysis, by Mode of Delivery

12.8. Asia Pacific Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Mode of Delivery

12.8.1. Intravenous

12.8.2. Subcutaneous

12.8.3. Oral

12.9. Asia Pacific Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel

12.10. Asia Pacific Systemic Lupus Erythematosus Treatment Market Forecast, by Distribution Channel

12.10.1. Hospital Pharmacies

12.10.2. Retail Pharmacies

12.10.3. Online Sales

13. Latin America Systemic Lupus Erythematosus Treatment Market Analysis

13.1. Key Findings

13.2. Latin America Systemic Lupus Erythematosus Treatment Market Overview

13.3. Latin America Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region

13.4. Latin America Systemic Lupus Erythematosus Treatment Market Forecast, by Country/Sub-region

13.4.1. Brazil

13.4.2. Mexico

13.4.3. Rest of Latin America

13.5. Latin America Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Drug

13.6. Latin America Systemic Lupus Erythematosus Treatment Market Forecast, by Drug

13.6.1. Antimalarial Drugs

13.6.1.1. Chloroquine

13.6.1.2. Hydrochloroquine

13.6.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)

13.6.2.1. Ibuprofen

13.6.2.2. Naproxen

13.6.2.3. Others

13.6.3. Corticosteroids

13.6.3.1. Prednisone

13.6.3.2. Hydrocortisone

13.6.3.3. Dexamethasone

13.6.3.4. Others

13.6.4. Immunosuppressive Drugs

13.6.4.1. Azathioprine

13.6.4.2. Cyclophosphamide

13.6.4.3. Methotrexate

13.6.4.4. Others

13.6.5. Others (Biologics, B-cell Modulators, etc.)

13.7. Latin America Systemic Lupus Erythematosus Treatment Market Value Share Analysis, by Mode of Delivery

13.8. Latin America Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Mode of Delivery

13.8.1. Intravenous

13.8.2. Subcutaneous

13.8.3. Oral

13.9. Latin America Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel

13.10. Latin America Systemic Lupus Erythematosus Treatment Market Forecast, by Distribution Channel

13.10.1. Hospital Pharmacies

13.10.2. Retail Pharmacies

13.10.3. Online Sales

14. Middle East & Africa Systemic Lupus Erythematosus Treatment Market Analysis

14.1. Key Findings

14.2. Middle East & Africa Systemic Lupus Erythematosus Treatment Market Overview

14.3. Middle East & Africa Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region

14.4. Middle East & Africa Systemic Lupus Erythematosus Treatment Market Forecast, by Country/Sub-region

14.4.1. GCC Countries

14.4.2. South Africa

14.4.3. Rest of Middle East & Africa

14.5. Middle East & Africa Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Drug

14.6. Middle East & Africa Systemic Lupus Erythematosus Treatment Market Forecast, by Drug

14.6.1. Antimalarial Drugs

14.6.1.1. Chloroquine

14.6.1.2. Hydrochloroquine

14.6.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)

14.6.2.1. Ibuprofen

14.6.2.2. Naproxen

14.6.2.3. Others

14.6.3. Corticosteroids

14.6.3.1. Prednisone

14.6.3.2. Hydrocortisone

14.6.3.3. Dexamethasone

14.6.3.4. Others

14.6.4. Immunosuppressive Drugs

14.6.4.1. Azathioprine

14.6.4.2. Cyclophosphamide

14.6.4.3. Methotrexate

14.6.4.4. Others

14.6.5. Others (Biologics, B-cell Modulators, etc.)

14.7. Middle East & Africa Systemic Lupus Erythematosus Treatment Market Value Share Analysis, by Mode of Delivery

14.8. Middle East & Africa Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Mode of Delivery

14.8.1. Intravenous

14.8.2. Subcutaneous

14.8.3. Oral

14.9. Middle East & Africa Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel

14.10. Middle East & Africa Systemic Lupus Erythematosus Treatment Market Forecast, by Distribution Channel

14.10.1. Hospital Pharmacies

14.10.2. Retail Pharmacies

14.10.3. Online Sales

15. Competitive Landscape

15.1. Competition Matrix

15.2. Company Profile

15.2.1. GlaxoSmithKline plc

15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

15.2.1.2. Financial Overview

15.2.1.3. Product Portfolio

15.2.1.4. SWOT Analysis

15.2.1.5. Strategic Overview

15.2.2. F. Hoffmann-La Roche Ltd.

15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

15.2.2.2. Financial Overview

15.2.2.3. Product Portfolio

15.2.2.4. SWOT Analysis

15.2.2.5. Strategic Overview

15.2.3. Pfizer, Inc.

15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)

15.2.3.2. Financial Overview

15.2.3.3. Product Portfolio

15.2.3.4. SWOT Analysis

15.2.3.5. Strategic Overview

15.2.4. AstraZeneca plc

15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)

15.2.4.2. Financial Overview

15.2.4.3. Product Portfolio

15.2.4.4. SWOT Analysis

15.2.4.5. Strategic Overview

15.2.5. Merck & Co., Inc.

15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

15.2.5.2. Financial Overview

15.2.5.3. Product Portfolio

15.2.5.4. SWOT Analysis

15.2.5.5. Strategic Overview

15.2.6. Bristol-Myers Squibb Company

15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)

15.2.6.2. Financial Overview

15.2.6.3. Product Portfolio

15.2.6.4. SWOT Analysis

15.2.6.5. Strategic Overview

15.2.7. Anthera Pharmaceuticals, Inc.

15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)

15.2.7.2. Financial Overview

15.2.7.3. Product Portfolio

15.2.7.4. SWOT Analysis

15.2.7.5. Strategic Overview

15.2.8. ImmuPharma PLC

15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

15.2.8.2. Product Portfolio

15.2.8.3. SWOT Analysis

15.2.8.4. Strategic Overview

15.2.9. Aurinia Pharmaceuticals, Inc.

15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)

15.2.9.2. Product Portfolio

15.2.9.3. SWOT Analysis

15.2.9.4. Strategic Overview